25 XP   0   0   10

Guizhou Xinbang Pharmaceutical Co Ltd
Buy, Hold or Sell?

Let's analyse Xinbang together

PenkeI guess you are interested in Guizhou Xinbang Pharmaceutical Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Guizhou Xinbang Pharmaceutical Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Guizhou Xinbang Pharmaceutical Co Ltd

I send you an email if I find something interesting about Guizhou Xinbang Pharmaceutical Co Ltd.

Quick analysis of Xinbang (30 sec.)










What can you expect buying and holding a share of Xinbang? (30 sec.)

How much money do you get?

How much money do you get?
¥0.02
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥3.68
Expected worth in 1 year
¥3.89
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
¥0.36
Return On Investment
9.0%

For what price can you sell your share?

Current Price per Share
¥3.96
Expected price per share
¥3.18 - ¥4.08
How sure are you?
50%

1. Valuation of Xinbang (5 min.)




Live pricePrice per Share (EOD)

¥3.96

Intrinsic Value Per Share

¥12.06 - ¥14.43

Total Value Per Share

¥15.74 - ¥18.10

2. Growth of Xinbang (5 min.)




Is Xinbang growing?

Current yearPrevious yearGrowGrow %
How rich?$986.8m$954.7m$27.2m2.8%

How much money is Xinbang making?

Current yearPrevious yearGrowGrow %
Making money$7.9m$10.4m-$2.5m-32.1%
Net Profit Margin3.6%4.8%--

How much money comes from the company's main activities?

3. Financial Health of Xinbang (5 min.)




What can you expect buying and holding a share of Xinbang? (5 min.)

Welcome investor! Xinbang's management wants to use your money to grow the business. In return you get a share of Xinbang.

What can you expect buying and holding a share of Xinbang?

First you should know what it really means to hold a share of Xinbang. And how you can make/lose money.

Speculation

The Price per Share of Xinbang is ¥3.96. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Xinbang.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Xinbang, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥3.68. Based on the TTM, the Book Value Change Per Share is ¥0.05 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.04 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Xinbang.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.010.2%0.000.1%0.010.1%0.000.0%0.000.0%
Usd Book Value Change Per Share0.000.1%0.010.2%0.000.1%0.000.0%0.010.3%
Usd Dividend Per Share0.000.0%0.000.1%0.000.1%0.000.1%0.010.1%
Usd Total Gains Per Share0.000.1%0.010.3%0.010.2%0.010.1%0.020.4%
Usd Price Per Share0.66-0.65-0.89-0.84-1.47-
Price to Earnings Ratio25.76--16.91-46.85-24.93-187.95-
Price-to-Total Gains Ratio190.02-86.99-130.62-87.44-160.27-
Price to Book Ratio1.31-1.30-1.88-2.04-6.76-
Price-to-Total Gains Ratio190.02-86.99-130.62-87.44-160.27-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.546876
Number of shares1828
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.00
Usd Total Gains Per Share0.010.01
Gains per Quarter (1828 shares)22.589.97
Gains per Year (1828 shares)90.3239.87
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1365480291130
272108170582270
31081622608733110
414521735011644150
518127144014555190
621732553017465230
725337962020376270
828943371023287310
932548780026198350
10362542890290109390

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%11.01.00.091.7%17.03.00.085.0%37.03.00.092.5%50.03.00.094.3%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%13.07.00.065.0%32.08.00.080.0%43.010.00.081.1%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%53.00.00.0100.0%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%17.03.00.085.0%36.04.00.090.0%49.04.00.092.5%

Fundamentals of Xinbang

About Guizhou Xinbang Pharmaceutical Co Ltd

Guizhou Xinbang Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells Chinese herbal medicines and other pharmaceutical products in China and internationally. The company offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medicine, gynecological treatment, and anti-infective drugs. It also operates in medical services; and pharmaceutical circulation business. The company was founded in 1995 and is headquartered in Guiyang, China.

Fundamental data was last updated by Penke on 2024-04-14 15:49:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Guizhou Xinbang Pharmaceutical Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Xinbang earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Xinbang to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 5.8% means that ¥0.06 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Guizhou Xinbang Pharmaceutical Co Ltd:

  • The MRQ is 5.8%. The company is making a profit. +1
  • The TTM is 3.6%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ5.8%TTM3.6%+2.2%
TTM3.6%YOY4.8%-1.2%
TTM3.6%5Y-1.4%+5.0%
5Y-1.4%10Y1.9%-3.3%
1.1.2. Return on Assets

Shows how efficient Xinbang is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Xinbang to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.9% Return on Assets means that Xinbang generated ¥0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Guizhou Xinbang Pharmaceutical Co Ltd:

  • The MRQ is 0.9%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.6%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.9%TTM0.6%+0.3%
TTM0.6%YOY0.8%-0.2%
TTM0.6%5Y-0.1%+0.7%
5Y-0.1%10Y0.3%-0.4%
1.1.3. Return on Equity

Shows how efficient Xinbang is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Xinbang to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.3% Return on Equity means Xinbang generated ¥0.01 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Guizhou Xinbang Pharmaceutical Co Ltd:

  • The MRQ is 1.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.3%TTM0.8%+0.5%
TTM0.8%YOY1.1%-0.3%
TTM0.8%5Y-0.6%+1.4%
5Y-0.6%10Y0.4%-1.0%

1.2. Operating Efficiency of Guizhou Xinbang Pharmaceutical Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Xinbang is operating .

  • Measures how much profit Xinbang makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Xinbang to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 8.5% means the company generated ¥0.09  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Guizhou Xinbang Pharmaceutical Co Ltd:

  • The MRQ is 8.5%. The company is operating less efficient.
  • The TTM is 6.0%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ8.5%TTM6.0%+2.6%
TTM6.0%YOY7.7%-1.7%
TTM6.0%5Y6.9%-0.9%
5Y6.9%10Y3.8%+3.0%
1.2.2. Operating Ratio

Measures how efficient Xinbang is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.70 means that the operating costs are ¥1.70 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Guizhou Xinbang Pharmaceutical Co Ltd:

  • The MRQ is 1.703. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.742. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.703TTM1.742-0.039
TTM1.742YOY1.720+0.021
TTM1.7425Y1.719+0.022
5Y1.71910Y1.268+0.451

1.3. Liquidity of Guizhou Xinbang Pharmaceutical Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Xinbang is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.37 means the company has ¥2.37 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Guizhou Xinbang Pharmaceutical Co Ltd:

  • The MRQ is 2.367. The company is able to pay all its short-term debts. +1
  • The TTM is 2.252. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.367TTM2.252+0.115
TTM2.252YOY2.060+0.192
TTM2.2525Y1.705+0.547
5Y1.70510Y0.915+0.790
1.3.2. Quick Ratio

Measures if Xinbang is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Xinbang to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.42 means the company can pay off ¥1.42 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Guizhou Xinbang Pharmaceutical Co Ltd:

  • The MRQ is 1.421. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.337. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.421TTM1.337+0.084
TTM1.337YOY1.297+0.040
TTM1.3375Y0.985+0.352
5Y0.98510Y0.800+0.184

1.4. Solvency of Guizhou Xinbang Pharmaceutical Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Xinbang assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Xinbang to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.26 means that Xinbang assets are financed with 25.8% credit (debt) and the remaining percentage (100% - 25.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Guizhou Xinbang Pharmaceutical Co Ltd:

  • The MRQ is 0.258. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.270. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.258TTM0.270-0.012
TTM0.270YOY0.288-0.018
TTM0.2705Y0.394-0.123
5Y0.39410Y0.427-0.034
1.4.2. Debt to Equity Ratio

Measures if Xinbang is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Xinbang to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 36.1% means that company has ¥0.36 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Guizhou Xinbang Pharmaceutical Co Ltd:

  • The MRQ is 0.361. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.385. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.361TTM0.385-0.023
TTM0.385YOY0.418-0.034
TTM0.3855Y0.735-0.350
5Y0.73510Y0.827-0.091

2. Market Valuation of Guizhou Xinbang Pharmaceutical Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Xinbang generates.

  • Above 15 is considered overpriced but always compare Xinbang to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 25.76 means the investor is paying ¥25.76 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Guizhou Xinbang Pharmaceutical Co Ltd:

  • The EOD is 21.252. Based on the earnings, the company is fair priced.
  • The MRQ is 25.760. Based on the earnings, the company is overpriced. -1
  • The TTM is -16.907. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD21.252MRQ25.760-4.508
MRQ25.760TTM-16.907+42.667
TTM-16.907YOY46.851-63.758
TTM-16.9075Y24.925-41.832
5Y24.92510Y187.950-163.025
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Guizhou Xinbang Pharmaceutical Co Ltd:

  • The EOD is 3.703. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 4.489. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 22.772. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.703MRQ4.489-0.786
MRQ4.489TTM22.772-18.283
TTM22.772YOY35.048-12.276
TTM22.7725Y105.396-82.624
5Y105.39610Y41.610+63.786
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Xinbang is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Guizhou Xinbang Pharmaceutical Co Ltd:

  • The EOD is 1.077. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.306. Based on the equity, the company is underpriced. +1
  • The TTM is 1.296. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.077MRQ1.306-0.229
MRQ1.306TTM1.296+0.010
TTM1.296YOY1.884-0.588
TTM1.2965Y2.042-0.746
5Y2.04210Y6.759-4.717
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Guizhou Xinbang Pharmaceutical Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0200.054-62%0.026-22%0.011+88%0.079-74%
Book Value Per Share--3.6763.658+0%3.410+8%3.055+20%2.719+35%
Current Ratio--2.3672.252+5%2.060+15%1.705+39%0.915+159%
Debt To Asset Ratio--0.2580.270-5%0.288-11%0.394-35%0.427-40%
Debt To Equity Ratio--0.3610.385-6%0.418-14%0.735-51%0.827-56%
Dividend Per Share--0.0050.036-86%0.026-81%0.029-83%0.036-86%
Eps--0.0470.036+29%0.037+24%-0.010+121%0.010+360%
Free Cash Flow Per Share--0.2670.085+213%0.063+324%0.068+292%0.020+1226%
Free Cash Flow To Equity Per Share--0.137-0.075+155%0.046+195%-0.019+114%0.032+329%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--14.426--------
Intrinsic Value_10Y_min--12.062--------
Intrinsic Value_1Y_max--0.420--------
Intrinsic Value_1Y_min--0.412--------
Intrinsic Value_3Y_max--2.045--------
Intrinsic Value_3Y_min--1.936--------
Intrinsic Value_5Y_max--4.611--------
Intrinsic Value_5Y_min--4.212--------
Market Cap7697645936.640-21%9330488966.4009213857854.320+1%13004671539.565-28%12059566070.716-23%20812762163.678-55%
Net Profit Margin--0.0580.036+61%0.048+21%-0.014+125%0.019+207%
Operating Margin--0.0850.060+43%0.077+11%0.069+24%0.038+123%
Operating Ratio--1.7031.742-2%1.720-1%1.719-1%1.268+34%
Pb Ratio1.077-21%1.3061.296+1%1.884-31%2.042-36%6.759-81%
Pe Ratio21.252-21%25.760-16.907+166%46.851-45%24.925+3%187.950-86%
Price Per Share3.960-21%4.8004.740+1%6.415-25%6.110-21%10.660-55%
Price To Free Cash Flow Ratio3.703-21%4.48922.772-80%35.048-87%105.396-96%41.610-89%
Price To Total Gains Ratio156.768-21%190.02286.993+118%130.623+45%87.440+117%160.265+19%
Quick Ratio--1.4211.337+6%1.297+10%0.985+44%0.800+78%
Return On Assets--0.0090.006+59%0.008+21%-0.001+114%0.003+234%
Return On Equity--0.0130.008+57%0.011+16%-0.006+144%0.004+231%
Total Gains Per Share--0.0250.089-72%0.052-52%0.039-36%0.115-78%
Usd Book Value--986828240.800982022814.947+0%954767617.168+3%831712205.167+19%735839239.539+34%
Usd Book Value Change Per Share--0.0030.007-62%0.004-22%0.001+88%0.011-74%
Usd Book Value Per Share--0.5080.505+0%0.471+8%0.422+20%0.376+35%
Usd Dividend Per Share--0.0010.005-86%0.004-81%0.004-83%0.005-86%
Usd Eps--0.0060.005+29%0.005+24%-0.001+121%0.001+360%
Usd Free Cash Flow--71763825.88722899306.749+213%17672189.156+306%18467650.703+289%3876480.292+1751%
Usd Free Cash Flow Per Share--0.0370.012+213%0.009+324%0.009+292%0.003+1226%
Usd Free Cash Flow To Equity Per Share--0.019-0.010+155%0.006+195%-0.003+114%0.004+329%
Usd Market Cap1063044903.850-21%1288540526.2601272433769.682+1%1795945139.614-28%1665426074.366-23%2874242454.804-55%
Usd Price Per Share0.547-21%0.6630.655+1%0.886-25%0.844-21%1.472-55%
Usd Profit--12505445.5127941531.565+57%10489484.606+19%-2808802.051+122%2607051.778+380%
Usd Revenue--216365627.472223964214.998-3%222168764.816-3%218894660.738-1%188909053.908+15%
Usd Total Gains Per Share--0.0030.012-72%0.007-52%0.005-36%0.016-78%
 EOD+4 -4MRQTTM+25 -10YOY+25 -105Y+26 -910Y+25 -10

3.2. Fundamental Score

Let's check the fundamental score of Guizhou Xinbang Pharmaceutical Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1521.252
Price to Book Ratio (EOD)Between0-11.077
Net Profit Margin (MRQ)Greater than00.058
Operating Margin (MRQ)Greater than00.085
Quick Ratio (MRQ)Greater than11.421
Current Ratio (MRQ)Greater than12.367
Debt to Asset Ratio (MRQ)Less than10.258
Debt to Equity Ratio (MRQ)Less than10.361
Return on Equity (MRQ)Greater than0.150.013
Return on Assets (MRQ)Greater than0.050.009
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Guizhou Xinbang Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.110
Ma 20Greater thanMa 503.807
Ma 50Greater thanMa 1003.862
Ma 100Greater thanMa 2004.098
OpenGreater thanClose3.920
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets9,627,215
Total Liabilities2,481,464
Total Stockholder Equity6,864,447
 As reported
Total Liabilities 2,481,464
Total Stockholder Equity+ 6,864,447
Total Assets = 9,627,215

Assets

Total Assets9,627,215
Total Current Assets5,782,007
Long-term Assets3,845,208
Total Current Assets
Cash And Cash Equivalents 1,058,408
Net Receivables 3,471,323
Inventory 1,058,454
Other Current Assets 193,823
Total Current Assets  (as reported)5,782,007
Total Current Assets  (calculated)5,782,007
+/- 0
Long-term Assets
Property Plant Equipment 2,563,314
Goodwill 603,749
Intangible Assets 182,953
Other Assets 151,354
Long-term Assets  (as reported)3,845,208
Long-term Assets  (calculated)3,501,370
+/- 343,839

Liabilities & Shareholders' Equity

Total Current Liabilities2,443,220
Long-term Liabilities38,244
Total Stockholder Equity6,864,447
Total Current Liabilities
Short Long Term Debt 1,126,868
Accounts payable 908,415
Other Current Liabilities 390,978
Total Current Liabilities  (as reported)2,443,220
Total Current Liabilities  (calculated)2,426,261
+/- 16,959
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt20,125
Other Liabilities 18,120
Long-term Liabilities  (as reported)38,244
Long-term Liabilities  (calculated)38,244
+/- 0
Total Stockholder Equity
Common Stock1,943,852
Retained Earnings 592,779
Total Stockholder Equity (as reported)6,864,447
Total Stockholder Equity (calculated)2,536,631
+/- 4,327,816
Other
Capital Stock1,943,852
Common Stock Shares Outstanding 1,943,852
Net Debt 68,460
Net Invested Capital 7,991,315
Net Tangible Assets 6,077,745
Net Working Capital 3,338,787
Property Plant and Equipment Gross 2,563,314



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302009-12-312008-12-312007-12-31
> Total Assets 
391,072
442,731
470,345
1,135,925
1,119,007
1,125,509
1,148,585
1,157,927
1,161,034
1,243,558
1,245,348
1,260,310
1,272,866
1,334,620
1,336,470
1,365,348
1,493,085
1,486,623
3,706,839
4,515,011
4,879,127
5,223,301
5,458,893
6,049,622
6,337,105
6,504,894
10,285,530
10,543,733
10,857,214
10,797,081
10,980,934
11,484,803
11,655,358
11,954,952
11,764,138
12,494,568
12,410,083
10,854,314
10,623,821
10,229,895
10,259,340
10,419,402
10,318,923
9,873,909
9,897,093
9,662,173
9,657,720
10,329,511
9,610,148
9,628,645
9,545,698
9,719,353
9,955,003
9,793,092
9,889,925
9,671,373
9,627,215
9,627,2159,671,3739,889,9259,793,0929,955,0039,719,3539,545,6989,628,6459,610,14810,329,5119,657,7209,662,1739,897,0939,873,90910,318,92310,419,40210,259,34010,229,89510,623,82110,854,31412,410,08312,494,56811,764,13811,954,95211,655,35811,484,80310,980,93410,797,08110,857,21410,543,73310,285,5306,504,8946,337,1056,049,6225,458,8935,223,3014,879,1274,515,0113,706,8391,486,6231,493,0851,365,3481,336,4701,334,6201,272,8661,260,3101,245,3481,243,5581,161,0341,157,9271,148,5851,125,5091,119,0071,135,925470,345442,731391,072
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,863,227
6,740,344
6,673,395
6,454,378
6,001,082
5,929,447
6,175,459
6,163,692
6,251,898
6,327,128
6,091,145
6,111,348
6,475,920
5,678,288
5,576,368
5,480,124
5,678,976
5,961,248
5,806,181
5,951,373
5,796,085
5,782,007
5,782,0075,796,0855,951,3735,806,1815,961,2485,678,9765,480,1245,576,3685,678,2886,475,9206,111,3486,091,1456,327,1286,251,8986,163,6926,175,4595,929,4476,001,0826,454,3786,673,3956,740,3446,863,22700000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,668,289
1,486,261
1,614,245
1,414,348
1,009,939
1,078,268
1,235,618
1,566,221
1,170,922
1,588,184
1,776,378
1,817,215
1,711,786
869,088
624,648
639,724
1,097,639
1,200,549
899,181
909,945
788,349
1,058,408
1,058,408788,349909,945899,1811,200,5491,097,639639,724624,648869,0881,711,7861,817,2151,776,3781,588,1841,170,9221,566,2211,235,6181,078,2681,009,9391,414,3481,614,2451,486,2611,668,28900000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
0
0
0
0
0
0
0
0
000000001,000000000000000000000000000000000000000000000000000
       Net Receivables 
112,605
108,174
133,377
135,454
154,464
162,407
170,891
181,289
190,796
229,918
237,097
241,813
262,744
305,179
308,150
308,216
327,844
309,859
840,357
988,568
1,352,576
1,594,845
1,657,091
1,995,412
2,067,088
2,059,048
2,192,752
2,561,352
2,879,910
2,766,628
3,017,519
3,023,911
3,115,104
3,040,019
3,409,709
3,766,236
3,798,060
3,613,371
2,782,701
2,950,637
2,920,070
3,473,513
3,227,829
3,892,973
3,574,843
3,208,547
3,181,830
3,554,508
3,537,234
3,678,777
3,646,284
3,421,645
3,518,111
3,539,925
3,049,334
3,763,436
3,471,323
3,471,3233,763,4363,049,3343,539,9253,518,1113,421,6453,646,2843,678,7773,537,2343,554,5083,181,8303,208,5473,574,8433,892,9733,227,8293,473,5132,920,0702,950,6372,782,7013,613,3713,798,0603,766,2363,409,7093,040,0193,115,1043,023,9113,017,5192,766,6282,879,9102,561,3522,192,7522,059,0482,067,0881,995,4121,657,0911,594,8451,352,576988,568840,357309,859327,844308,216308,150305,179262,744241,813237,097229,918190,796181,289170,891162,407154,464135,454133,377108,174112,605
       Inventory 
34,454
62,093
66,077
60,331
73,327
71,640
72,533
79,469
109,946
142,254
153,163
156,837
167,286
175,674
194,718
245,368
284,742
326,514
474,892
530,355
608,136
544,592
580,083
632,713
657,168
614,856
720,017
711,028
864,723
744,432
701,543
685,583
628,826
700,032
772,720
903,739
1,052,202
1,044,456
1,000,267
924,975
970,530
994,315
963,707
802,718
826,560
843,394
829,964
920,384
951,478
935,708
905,923
919,691
994,969
1,032,718
1,063,894
1,008,647
1,058,454
1,058,4541,008,6471,063,8941,032,718994,969919,691905,923935,708951,478920,384829,964843,394826,560802,718963,707994,315970,530924,9751,000,2671,044,4561,052,202903,739772,720700,032628,826685,583701,543744,432864,723711,028720,017614,856657,168632,713580,083544,592608,136530,355474,892326,514284,742245,368194,718175,674167,286156,837153,163142,254109,94679,46972,53371,64073,32760,33166,07762,09334,454
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,169,443
4,228,813
4,329,893
4,243,942
4,155,231
3,622,010
3,569,965
3,571,029
3,546,371
3,853,590
3,931,860
4,052,277
4,065,574
4,040,377
3,993,755
3,986,911
3,938,552
3,875,288
3,845,208
3,845,2083,875,2883,938,5523,986,9113,993,7554,040,3774,065,5744,052,2773,931,8603,853,5903,546,3713,571,0293,569,9653,622,0104,155,2314,243,9424,329,8934,228,8134,169,44300000000000000000000000000000000000000
       Property Plant Equipment 
139,760
140,747
141,043
147,949
156,689
199,983
208,368
251,087
267,730
281,415
283,195
294,455
289,400
334,225
332,724
358,271
331,452
362,079
799,133
794,441
830,955
866,484
1,047,747
1,264,780
1,317,556
1,754,808
1,898,178
2,091,569
2,141,979
2,360,197
2,411,028
2,497,913
2,671,094
2,707,426
2,695,024
2,723,331
2,731,012
2,774,631
2,770,163
2,776,834
2,829,631
2,750,513
2,654,245
2,329,273
2,289,285
2,323,201
2,301,621
2,632,108
2,636,703
2,705,891
2,725,797
2,704,745
2,669,816
2,671,739
2,631,043
2,586,641
2,563,314
2,563,3142,586,6412,631,0432,671,7392,669,8162,704,7452,725,7972,705,8912,636,7032,632,1082,301,6212,323,2012,289,2852,329,2732,654,2452,750,5132,829,6312,776,8342,770,1632,774,6312,731,0122,723,3312,695,0242,707,4262,671,0942,497,9132,411,0282,360,1972,141,9792,091,5691,898,1781,754,8081,317,5561,264,7801,047,747866,484830,955794,441799,133362,079331,452358,271332,724334,225289,400294,455283,195281,415267,730251,087208,368199,983156,689147,949141,043140,747139,760
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
635,187
635,277
643,019
647,585
647,585
647,585
647,585
647,585
2,369,451
2,356,941
2,356,941
2,318,991
2,318,991
2,318,991
2,318,991
2,318,991
2,318,991
2,318,991
2,318,991
778,215
778,215
778,215
778,215
778,215
778,215
605,540
605,540
605,540
605,540
607,347
607,347
607,347
607,347
607,347
607,347
607,347
607,347
603,749
603,749
603,749603,749607,347607,347607,347607,347607,347607,347607,347607,347605,540605,540605,540605,540778,215778,215778,215778,215778,215778,2152,318,9912,318,9912,318,9912,318,9912,318,9912,318,9912,318,9912,318,9912,356,9412,356,9412,369,451647,585647,585647,585647,585647,585643,019635,277635,187000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
128,671
88,755
88,448
88,448
147,069
146,879
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000146,879147,06988,44888,44888,755128,67100000000000000000000000000000000000
       Intangible Assets 
9,893
9,379
3,468
3,251
11,268
3,034
10,951
2,817
10,446
4,786
12,276
4,443
11,775
4,000
62,081
3,582
69,105
3,140
782,004
781,157
788,928
791,954
791,842
798,611
804,098
813,558
2,656,019
2,650,679
2,645,431
2,667,531
2,655,914
2,664,226
2,660,131
2,655,580
2,650,113
330,476
326,784
328,044
321,797
136,935
355,993
307,784
300,717
219,917
220,068
219,559
216,337
215,328
212,197
217,650
214,135
210,607
207,297
204,373
200,704
186,447
182,953
182,953186,447200,704204,373207,297210,607214,135217,650212,197215,328216,337219,559220,068219,917300,717307,784355,993136,935321,797328,044326,784330,4762,650,1132,655,5802,660,1312,664,2262,655,9142,667,5312,645,4312,650,6792,656,019813,558804,098798,611791,842791,954788,928781,157782,0043,14069,1053,58262,0814,00011,7754,44312,2764,78610,4462,81710,9513,03411,2683,2513,4689,3799,893
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
36,000
36,000
4,329,893
4,243,942
4,155,231
0
2,289,285
0
0
0
0
0
0
0
0
0
0
0
0
0000000000002,289,28504,155,2314,243,9424,329,89336,00036,00000000000000000000000000000000000000000
> Total Liabilities 
216,993
235,039
217,514
199,568
175,127
165,810
182,363
201,163
196,164
264,023
258,767
267,214
270,913
311,990
307,086
350,076
469,162
450,692
1,673,259
2,155,500
2,479,169
2,765,398
2,966,838
3,466,717
3,703,484
3,835,886
3,967,078
4,198,542
4,432,735
4,312,074
4,449,781
4,901,605
4,971,483
5,196,306
5,245,148
5,852,426
5,684,113
5,685,795
5,668,913
5,220,383
5,195,072
5,371,084
5,370,931
4,860,350
4,802,140
4,493,670
4,411,189
3,501,521
2,802,684
2,800,144
2,635,210
2,821,275
2,937,686
2,728,043
2,763,289
2,564,991
2,481,464
2,481,4642,564,9912,763,2892,728,0432,937,6862,821,2752,635,2102,800,1442,802,6843,501,5214,411,1894,493,6704,802,1404,860,3505,370,9315,371,0845,195,0725,220,3835,668,9135,685,7955,684,1135,852,4265,245,1485,196,3064,971,4834,901,6054,449,7814,312,0744,432,7354,198,5423,967,0783,835,8863,703,4843,466,7172,966,8382,765,3982,479,1692,155,5001,673,259450,692469,162350,076307,086311,990270,913267,214258,767264,023196,164201,163182,363165,810175,127199,568217,514235,039216,993
   > Total Current Liabilities 
187,903
229,068
213,997
196,051
171,631
165,793
182,346
201,146
196,147
253,118
247,363
255,510
256,368
291,255
286,000
327,459
446,335
426,925
1,543,849
2,089,495
2,342,816
2,708,614
2,912,668
3,395,326
3,637,616
3,771,923
3,834,763
4,150,574
4,384,759
4,283,859
4,421,637
4,873,600
4,944,604
4,874,117
4,893,005
5,505,921
5,336,951
5,337,290
5,320,061
4,871,826
4,847,058
5,009,469
5,008,903
4,537,760
4,479,461
4,470,440
4,390,170
3,457,067
2,759,556
2,754,617
2,592,914
2,778,576
2,896,623
2,686,811
2,723,547
2,525,691
2,443,220
2,443,2202,525,6912,723,5472,686,8112,896,6232,778,5762,592,9142,754,6172,759,5563,457,0674,390,1704,470,4404,479,4614,537,7605,008,9035,009,4694,847,0584,871,8265,320,0615,337,2905,336,9515,505,9214,893,0054,874,1174,944,6044,873,6004,421,6374,283,8594,384,7594,150,5743,834,7633,771,9233,637,6163,395,3262,912,6682,708,6142,342,8162,089,4951,543,849426,925446,335327,459286,000291,255256,368255,510247,363253,118196,147201,146182,346165,793171,631196,051213,997229,068187,903
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,911,190
3,450,360
3,376,360
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000003,376,3603,450,3603,911,19000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,911,190
3,450,360
3,376,360
3,435,360
3,751,360
3,441,360
3,403,500
3,382,500
3,477,000
2,298,970
1,619,290
1,362,290
1,323,290
1,623,190
1,637,190
1,343,242
1,431,966
1,264,182
1,126,868
1,126,8681,264,1821,431,9661,343,2421,637,1901,623,1901,323,2901,362,2901,619,2902,298,9703,477,0003,382,5003,403,5003,441,3603,751,3603,435,3603,376,3603,450,3603,911,19000000000000000000000000000000000000000
       Accounts payable 
12,574
8,008
12,788
4,819
12,413
12,655
15,387
15,582
22,590
45,681
32,753
16,275
11,544
37,515
40,911
60,719
45,190
64,940
524,598
616,234
723,048
736,766
748,244
921,047
1,192,264
1,143,018
1,008,783
1,308,270
1,385,805
1,195,562
1,453,744
1,245,627
1,295,392
1,198,433
1,100,425
1,279,552
1,154,922
1,060,405
975,729
1,006,246
954,640
1,020,934
829,826
713,824
679,341
788,572
626,655
852,799
835,785
993,431
892,259
787,567
853,828
977,236
874,752
815,799
908,415
908,415815,799874,752977,236853,828787,567892,259993,431835,785852,799626,655788,572679,341713,824829,8261,020,934954,6401,006,246975,7291,060,4051,154,9221,279,5521,100,4251,198,4331,295,3921,245,6271,453,7441,195,5621,385,8051,308,2701,008,7831,143,0181,192,264921,047748,244736,766723,048616,234524,59864,94045,19060,71940,91137,51511,54416,27532,75345,68122,59015,58215,38712,65512,4134,81912,7888,00812,574
       Other Current Liabilities 
19,469
25,110
27,259
23,372
21,358
18,278
22,099
22,704
22,557
12,577
9,750
9,375
14,964
18,630
17,729
38,880
50,485
40,125
129,390
122,901
165,909
164,389
113,564
384,419
338,492
288,045
363,602
272,943
308,602
296,744
234,741
276,620
296,852
283,324
485,221
367,537
404,845
363,860
409,877
371,712
485,757
394,146
381,371
242,956
371,575
237,532
270,730
234,411
288,953
375,951
357,502
278,739
386,111
306,004
2,268
349,028
390,978
390,978349,0282,268306,004386,111278,739357,502375,951288,953234,411270,730237,532371,575242,956381,371394,146485,757371,712409,877363,860404,845367,537485,221283,324296,852276,620234,741296,744308,602272,943363,602288,045338,492384,419113,564164,389165,909122,901129,39040,12550,48538,88017,72918,63014,9649,3759,75012,57722,55722,70422,09918,27821,35823,37227,25925,11019,469
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
348,851
348,557
348,014
361,615
362,028
322,589
322,679
23,230
21,019
44,454
43,128
45,526
42,297
42,699
41,062
41,232
39,742
39,300
38,244
38,24439,30039,74241,23241,06242,69942,29745,52643,12844,45421,01923,230322,679322,589362,028361,615348,014348,557348,85100000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-3,911,190
-3,450,360
-3,376,360
0
0
0
0
0
0
24,181
23,479
24,813
23,584
23,915
23,218
22,023
21,077
21,070
20,125
20,12521,07021,07722,02323,21823,91523,58424,81323,47924,181000000-3,376,360-3,450,360-3,911,19000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
372
323,787
372
353
353
353
353
353
338
338
338
338
323
323
323
323
308
308
308
308308308323323323323338338338338353353353353353372323,78737200000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
93,179
129,490
132,245
130,478
125,853
168,003
208,170
221,388
192,484
187,727
153,189
155,929
124,117
125,961
118,362
115,612
109,484
103,544
97,214
0
86,896
83,798
83,79886,896097,214103,544109,484115,612118,362125,961124,117155,929153,189187,727192,484221,388208,170168,003125,853130,478132,245129,49093,17900000000000000000000000000000000000
> Total Stockholder Equity
172,647
206,487
253,177
936,793
944,362
960,219
966,779
957,370
965,521
980,258
987,331
993,873
1,002,757
1,017,671
1,024,773
1,015,173
1,023,805
1,034,902
1,978,878
2,299,607
2,338,635
2,396,918
2,429,969
2,448,903
2,498,474
2,541,866
6,201,998
6,225,488
6,295,207
6,352,063
6,404,696
6,447,932
6,548,814
6,615,307
6,372,054
6,443,145
6,532,100
4,967,458
4,767,455
4,810,244
4,881,212
4,837,090
4,736,057
4,780,567
4,868,028
4,918,340
4,990,521
6,568,219
6,549,771
6,619,762
6,693,239
6,662,375
6,771,907
6,808,452
6,861,396
6,847,842
6,864,447
6,864,4476,847,8426,861,3966,808,4526,771,9076,662,3756,693,2396,619,7626,549,7716,568,2194,990,5214,918,3404,868,0284,780,5674,736,0574,837,0904,881,2124,810,2444,767,4554,967,4586,532,1006,443,1456,372,0546,615,3076,548,8146,447,9326,404,6966,352,0636,295,2076,225,4886,201,9982,541,8662,498,4742,448,9032,429,9692,396,9182,338,6352,299,6071,978,8781,034,9021,023,8051,015,1731,024,7731,017,6711,002,757993,873987,331980,258965,521957,370966,779960,219944,362936,793253,177206,487172,647
   Common Stock
65,100
65,100
65,100
86,800
86,800
86,800
86,800
173,600
173,600
173,600
173,600
173,600
173,600
173,600
173,600
173,600
173,600
173,600
231,279
500,455
500,455
500,455
500,455
1,251,136
1,251,136
1,251,136
1,704,896
1,704,896
1,704,896
1,704,896
1,704,896
1,704,896
1,704,896
1,704,896
1,704,896
1,667,229
1,667,229
1,667,229
1,667,229
1,667,229
1,667,229
1,667,229
1,667,229
1,667,229
1,667,229
1,667,229
1,667,229
2,027,229
2,027,229
2,027,229
2,027,229
2,027,229
2,027,229
1,943,852
0
1,943,852
1,943,852
1,943,8521,943,85201,943,8522,027,2292,027,2292,027,2292,027,2292,027,2292,027,2291,667,2291,667,2291,667,2291,667,2291,667,2291,667,2291,667,2291,667,2291,667,2291,667,2291,667,2291,667,2291,704,8961,704,8961,704,8961,704,8961,704,8961,704,8961,704,8961,704,8961,704,8961,251,1361,251,1361,251,136500,455500,455500,455500,455231,279173,600173,600173,600173,600173,600173,600173,600173,600173,600173,600173,60086,80086,80086,80086,80065,10065,10065,100
   Retained Earnings 
62,492
92,809
134,502
156,783
164,352
168,318
174,879
165,469
173,620
183,557
190,631
197,172
206,056
215,945
223,048
221,643
230,275
242,051
288,093
313,290
353,261
411,716
444,767
463,701
513,272
556,665
600,273
634,690
704,719
750,730
803,142
846,114
946,185
1,018,967
1,092,623
1,164,589
1,232,869
-308,791
-301,195
-241,681
-162,847
-72,489
-85,506
-55,605
31,856
82,168
154,349
234,729
292,177
354,987
428,464
369,855
479,387
462,835
426,157
502,225
592,779
592,779502,225426,157462,835479,387369,855428,464354,987292,177234,729154,34982,16831,856-55,605-85,506-72,489-162,847-241,681-301,195-308,7911,232,8691,164,5891,092,6231,018,967946,185846,114803,142750,730704,719634,690600,273556,665513,272463,701444,767411,716353,261313,290288,093242,051230,275221,643223,048215,945206,056197,172190,631183,557173,620165,469174,879168,318164,352156,783134,50292,80962,492
   Capital Surplus 000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000-299,9860000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-16,960
3,716
-15,304
-17,088
-15,088
-13,911
-12,782
-14,609
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000-14,609-12,782-13,911-15,088-17,088-15,3043,716-16,96000000000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue6,487,016
Cost of Revenue-5,254,627
Gross Profit1,232,3891,232,389
 
Operating Income (+$)
Gross Profit1,232,389
Operating Expense-6,047,246
Operating Income439,770-4,814,857
 
Operating Expense (+$)
Research Development2,804
Selling General Administrative497,742
Selling And Marketing Expenses-
Operating Expense6,047,246500,546
 
Net Interest Income (+$)
Interest Income12,229
Interest Expense-36,700
Other Finance Cost-1,812
Net Interest Income-22,658
 
Pretax Income (+$)
Operating Income439,770
Net Interest Income-22,658
Other Non-Operating Income Expenses-
Income Before Tax (EBT)339,315439,770
EBIT - interestExpense = -36,700
230,023
266,722
Interest Expense36,700
Earnings Before Interest and Taxes (EBIT)-376,014
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax339,315
Tax Provision-44,175
Net Income From Continuing Ops295,140295,140
Net Income230,023
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-22,658
 

Technical Analysis of Xinbang
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Xinbang. The general trend of Xinbang is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Xinbang's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Guizhou Xinbang Pharmaceutical Co Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 4.03 < 4.04 < 4.08.

The bearish price targets are: 3.93 > 3.6 > 3.18.

Tweet this
Guizhou Xinbang Pharmaceutical Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Guizhou Xinbang Pharmaceutical Co Ltd. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Guizhou Xinbang Pharmaceutical Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Guizhou Xinbang Pharmaceutical Co Ltd. The current macd is -0.00024923.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xinbang price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Xinbang. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Xinbang price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Guizhou Xinbang Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartGuizhou Xinbang Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Guizhou Xinbang Pharmaceutical Co Ltd. The current adx is 17.40.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Xinbang shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Guizhou Xinbang Pharmaceutical Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Guizhou Xinbang Pharmaceutical Co Ltd. The current sar is 3.65515809.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Guizhou Xinbang Pharmaceutical Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Guizhou Xinbang Pharmaceutical Co Ltd. The current rsi is 60.11. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Guizhou Xinbang Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) ChartGuizhou Xinbang Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Guizhou Xinbang Pharmaceutical Co Ltd. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xinbang price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Guizhou Xinbang Pharmaceutical Co Ltd Daily Stochastic Oscillator ChartGuizhou Xinbang Pharmaceutical Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Guizhou Xinbang Pharmaceutical Co Ltd. The current cci is 139.26.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Guizhou Xinbang Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) ChartGuizhou Xinbang Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Guizhou Xinbang Pharmaceutical Co Ltd. The current cmo is 35.69.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Guizhou Xinbang Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) ChartGuizhou Xinbang Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Guizhou Xinbang Pharmaceutical Co Ltd. The current willr is -2.7027027.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Guizhou Xinbang Pharmaceutical Co Ltd Daily Williams %R ChartGuizhou Xinbang Pharmaceutical Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Guizhou Xinbang Pharmaceutical Co Ltd.

Guizhou Xinbang Pharmaceutical Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Guizhou Xinbang Pharmaceutical Co Ltd. The current atr is 0.09519704.

Guizhou Xinbang Pharmaceutical Co Ltd Daily Average True Range (ATR) ChartGuizhou Xinbang Pharmaceutical Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Guizhou Xinbang Pharmaceutical Co Ltd. The current obv is 154,670,100.

Guizhou Xinbang Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) ChartGuizhou Xinbang Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Guizhou Xinbang Pharmaceutical Co Ltd. The current mfi is 60.40.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Guizhou Xinbang Pharmaceutical Co Ltd Daily Money Flow Index (MFI) ChartGuizhou Xinbang Pharmaceutical Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Guizhou Xinbang Pharmaceutical Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Guizhou Xinbang Pharmaceutical Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Guizhou Xinbang Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.110
Ma 20Greater thanMa 503.807
Ma 50Greater thanMa 1003.862
Ma 100Greater thanMa 2004.098
OpenGreater thanClose3.920
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Xinbang with someone you think should read this too:
  • Are you bullish or bearish on Xinbang? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Xinbang? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Guizhou Xinbang Pharmaceutical Co Ltd

I send you an email if I find something interesting about Guizhou Xinbang Pharmaceutical Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Guizhou Xinbang Pharmaceutical Co Ltd.

Receive notifications about Guizhou Xinbang Pharmaceutical Co Ltd in your mailbox!